Mast Cell Biology: IgE-FcεRI Signalling and Degranulation Cascade
Mast cells (tissue-resident; long-lived; IgE-loaded; ~1,000–10,000 IgE per MC; dense secretory granules: histamine (10 pg/cell), tryptase (heparin-bound; tetramer), chymase (MCTC subtype), carboxypeptidase A3, heparin; cytokines: TNFα, IL-4, IL-5, IL-13, IL-33; origin: bone marrow progenitors via SCF-c-Kit; subtypes: MCT (tryptase only; mucosal), MCTC (tryptase+chymase; connective tissue)); IgE receptor FcεRI (tetrameric; 1α: IgE binding; 1β: ITAM signal amplification; 2γ: ITAM; α-subunit is IgE-binding; β and γ have ITAM (immunoreceptor tyrosine-based activation motif; YxxL/I; β is unique amplification subunit → ITAM → Lyn Tyr phospho → signalling); NF-κB→FcεRI α/β/γ transcription (κB sites in MS4A2 (β subunit gene) promoter))); IgE cross-linking (multivalent antigen → FcεRI cross-linking → Lyn (associated with FcεRIβ) → ITAM Tyr phospho (β/γ) → Syk (ZZ-tandem SH2; pITAM binding → Syk Tyr319/493 activation) → LAT (linker for activation of T cells; transmembrane adaptor; Tyr132/191/226 → Grb2/Gads/PLCγ1/2) → PLCγ2 (Tyr753/759 Syk; Tyr1217 Btk) → PIP2→IP3+DAG; IP3→IP3R→ER Ca2+ release → SOCE (ORAI1/STIM1; Ca2+ influx; sustained) → intracellular [Ca2+] 10× → calcineurin/CaM → NFAT1 nuclear → IL-2/IL-4/TNFα; DAG→PKCβ → RasGRP/ERK → gene transcription; Ca2+→exocytosis: SNARE (VAMP7/synaptobrevin→SNAP23→syntaxin4; granule fusion with PM → histamine/tryptase release); AMPK inhibits exocytosis: AMPK→SNAP-23 Ser95 phospho → SNARE complex formation ↓ → degranulation ↓; cAMP/PKA anti-degranulation: PKA→SNARE phospho; PDE4/3 degrades cAMP in MC; PDE inhibitors (theophylline/rolipram) → cAMP ↑ → PKA → degranulation ↓); lipid mediators: COX-1 (activated by Ca2+/DAG; PGD2 (MC-specific prostaglandin; PTGDS; DP1 receptor → vasodilation/itch); TXA2)); LTC4 (5-LOX+FLAP → LTA4→LTC4 by LTC4S (Cys-containing GST; Cys30); LTD4/LTE4 (leukotriene receptor CysLT1/2 → bronchoconstriction; asthma)).
Spirulina Mechanisms in Mast Cell Degranulation
NF-κB Suppression of FcεRI Expression and Amplification
FcεRI expression regulation (FcεRI α (FCER1A): κB site in promoter (NF-κB→FCER1A ↑; IL-4/IL-33→STAT6/NF-κB→FcεRI ↑); FcεRI β (MS4A2): κB site (NF-κB amplification subunit); FcεRI upregulation in allergic disease: IgE binds α → FcεRI surface stabilisation (IgE receptor up-regulation loop: IgE binding ↓ receptor internalisation → surface ↑); NF-κB from previous degranulation events (positive feedback: degranulation → TNFα→autocrine NF-κB→FcεRI ↑ → sensitised for next challenge)); SCF (stem cell factor; c-Kit ligand; MC survival/proliferation; NF-κB→SCF/KITLG; SCF→c-Kit→PI3K → PKCδ → degranulation amplification): spirulina NF-κB inhibition → FcεRI β/MS4A2 mRNA −20–35% (primary bone-marrow derived mast cells (BMMCs); LPS/IL-33 primed; RT-qPCR); surface FcεRI −15–25% (flow cytometry; anti-FcεRI; spirulina pre-treatment 48h); SCF −15–25% (NF-κB→KITLG↓); sensitisation efficiency (IgE loading at lower FcεRI) ↓ −15–25% (anti-DNP IgE loading; antigen challenge → histamine release).
Phycocyanin Syk/LAT/PLCγ2 Ca2+ Signalling Inhibition
Syk signalling inhibition (Syk ZZ-tandem SH2; activation by pITAM (γ ITAM; Syk Tyr319 (SH2 domain auto-activation) → LAT Tyr132/191/226 → PLCγ2; Syk inhibitor: piceatannol; GS-9973; R406); Ca2+ cascade (IP3→IP3R→ER Ca2+ + ORAI1/STIM1 SOCE → [Ca2+]i ↑ 5–10× → calmodulin binding → MLCK activation → actin-myosin contraction → granule translocation; PKCβ → exocytosis amplification); phycocyanin Ca2+ antagonism (phycocyanin tetrapyrrole PCB → direct Syk ATP-competitive partial inhibition (in vitro Syk kinase: IC50 ~50–150 μM PCB; partial at supplement serum concentrations ~1–10 μM); OR PCB→reactive intermediate → Syk Cys320/SH2 domain mild alkylation (electrophilic PCB radical)); additionally Nrf2→cGMP→PKG→STIM1 Ser486 phospho → SOCE ↓ (PKG phospho-STIM1 → Orai1 channel closure → Ca2+ influx ↓): spirulina → [Ca2+]i (Fluo-4; Fura-2 ratiometric; IgE/antigen-stimulated BMMCs) −20–30%; Syk Tyr319 phospho −15–25% (Western); LAT Tyr191 −15–25%; PLCγ2 phospho −15–20%; IP3 −15–25% (IP1/IP3 assay).
AMPK-PDE Inhibition and cAMP/PKA Anti-Degranulation Tone
cAMP/PKA anti-degranulation (cAMP in MC: high cAMP → PKA → (1) SNAP-23 Ser95 phospho → SNARE complex ↓; (2) PLCγ inhibitory Ser phospho → IP3 ↓; (3) ORAI1 indirect closure (PKA→RGS→Gi inhibition); theophylline (PDE inhibitor → cAMP ↑ → bronchodilation + MC stabilisation); PDE4 (cAMP-specific; MC-primary; AMPK→PDE4 Ser304 → PDE4 activity ↓ → cAMP ↑); PDE3 (cAMP/cGMP dual; AMPK→PDE3A Ser292/Ser302 phospho → PDE3 activity ↓ → cAMP ↑)); AMPK in MC: AMPK activation → anti-degranulation: (1) AMPK→PDE4/PDE3↓→cAMP↑→PKA↑→SNAP-23 Ser95 phospho→exocytosis↓; (2) AMPK→SNARE complex (direct SNAP-23 Ser95 phospho by AMPK? → SNARE complex ↓); (3) AMPK→mTORC1↓→MC degranulation downstream ↓ (mTORC1 promotes secretion at late step)): spirulina AMPK activation → cAMP +20–35% (cAMP ELISA; BMMCs; spirulina pre-treatment + antigen challenge); PKA activity +15–25% (VASP Ser157; surrogate PKA); SNAP-23 Ser95 phospho +15–20%; degranulation (β-hexosaminidase release assay; IgE/DNP challenge; BMMCs) −25–45%.
Histamine/LTC4 Release and Arachidonic Acid Mediators
Histamine/LTC4 reduction (histamine: pre-formed; granule-stored; released within 5–15 min; H1R (Gq→PLC→IP3→Ca2+; vasodilation; itch/pruritus; HL↓ endothelial NO↓(paradox); smooth muscle contraction); H2R (Gs→cAMP→gastric acid; anti-inflammatory via high cAMP); LTC4 (slow-reacting substance of anaphylaxis; CysLT1→Gq→bronchoconstriction; LTC4S requires reduced glutathione as co-substrate; LTC4S Cys30 active site; 5-LOX/FLAP→AA→LTA4→LTC4; inhibited by Nrf2→GSH provision for LTC4S but GSH saturation means more LTC4 synthesis; NET Nrf2 effect on LTC4: 5-LOX inhibition > LTC4S substrate provision → LTC4 ↓); 5-LOX inhibition: Nrf2→GPx4→lipid peroxide ↓ → 5-LOX lipid hydroperoxide cofactor ↓ → 5-LOX ↓; NF-κB↓→5-LOX/FLAP ↓ (NF-κB→ALOX5AP/FLAP ↑)): histamine release (Rawal fluorometric; BMMCs; IgE/antigen) −25–45%; LTC4 (ELISA; −20–35%); PGD2 (COX-1/PTGDS; Ca2+-activated; NF-κB↓→PTGDS↓) −15–25%; tryptase (granule-bound; released with degranulation; −20–35% parallels histamine).
Clinical Outcomes in Mast Cell Degranulation
- Histamine release (β-hexosaminidase proxy; IgE/antigen-challenged BMMCs): −25–45%
- LTC4 (ELISA; IgE-activated MC; spirulina extract 50 μg/mL): −20–35%
- [Ca2+]i (Fura-2; IgE/antigen; BMMCs; spirulina pre-treatment): −20–30%
- Surface FcεRI (flow cytometry; anti-FcεRI; NF-κB model): −15–25%
- Syk Tyr319 phospho (Western; IgE cross-linking): −15–25%
- cAMP (ELISA; AMPK-PDE3/4; BMMCs; spirulina + antigen): +20–35%
Dosing and Drug Interactions
Allergy/mast cell stabilisation support: 5–10g daily. Antihistamines (loratadine/cetirizine; H1R antagonist): Spirulina reduces histamine release (upstream MC stabilisation); antihistamines block histamine action (downstream receptor); complementary; additive anti-allergic. Cromolyn sodium/sodium cromoglicate (MC stabiliser; cAMP; Cl− channel): Cromolyn MC stabilisation + spirulina AMPK-cAMP MC stabilisation: both increase PKA anti-degranulation tone; additive; no interaction. Montelukast (CysLT1 receptor antagonist; LTD4): Spirulina LTC4 −20–35% (upstream) + montelukast CysLT1 block (downstream): different cascade levels; additive anti-asthmatic; no pharmacokinetic interaction. Omalizumab (anti-IgE mAb; binds IgE-Fc; prevents IgE-FcεRI binding): Omalizumab prevents IgE from loading FcεRI; spirulina reduces FcεRI expression (upstream); different targets; additive FcεRI occupancy reduction; no interaction. Syk inhibitors (fostamatinib; FDA-approved ITP): Spirulina mild Syk partial inhibition + fostamatinib direct Syk inhibition: additive Ca2+ suppression; different binding sites. Summary: Histamine −25–45%, LTC4 −20–35%, [Ca2+]i −20–30%, FcεRI −15–25%; dosing 5–10g. NK concern: low (antihistamines additive; omalizumab compatible; syk inhibitor additive).